Susquehanna International Group, LLP Genmab A/S Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$23.84 - $28.48 $64,368 - $76,896	2,700 Added 18.49%	17,300 $421,000
Q2 2024 Aug 15, 2024	SELL	$25.13 - $30.27 $258,839 - $311,781	-10,300 Reduced 41.37%	14,600 $366,000
Q1 2024 May 07, 2024	BUY	$26.43 - $32.77 $658,107 - $815,973	24,900 New	24,900 $744,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $176,350 - $211,200	5,000 Added 38.46%	18,000 $634,000
Q2 2023 Aug 11, 2023	SELL	$37.4 - $42.94 $3.29 Million - $3.78 Million	-88,000 Reduced 87.13%	13,000 $494,000
Q1 2023 May 16, 2023	BUY	$34.88 - $43.22 $2.6 Million - $3.22 Million	74,500 Added 281.13%	101,000 $3.81 Million
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $895,699 - $1.25 Million	26,500 New	26,500 $1.12 Million

238

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.3B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.